Nereus raises $20 million as mid-stage lung cancer trial shows promise
This article was originally published in Scrip
Nereus Pharmaceuticals, which recently completed enrolment in a Phase II lung cancer trial with its lead candidate plinabulin (NPI-2358), has raised $20 million in a financing round led by HBM BioVentures.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.